MA34738B1 - Neutralisation d'anticorps anti-ccl20 - Google Patents

Neutralisation d'anticorps anti-ccl20

Info

Publication number
MA34738B1
MA34738B1 MA36013A MA36013A MA34738B1 MA 34738 B1 MA34738 B1 MA 34738B1 MA 36013 A MA36013 A MA 36013A MA 36013 A MA36013 A MA 36013A MA 34738 B1 MA34738 B1 MA 34738B1
Authority
MA
Morocco
Prior art keywords
antibodies
ccl20
relates
neutralization
present
Prior art date
Application number
MA36013A
Other languages
English (en)
Inventor
Toshio Imai
James Bradford Kline
Tetsu Kawano
Luigi Grasso
Yoshimasa Sakamoto
Jared Spidel
Miyuki Nishimura
Kenzo Muramoto
Tatsuo Horizoe
Original Assignee
Horizoe Tastuo
Toshio Imai
James Bradford Kline
Tetsu Kawano
Luigi Grasso
Yoshimasa Sakamoto
Jared Spidel
Miyuki Nishimura
Kenzo Muramoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizoe Tastuo, Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto filed Critical Horizoe Tastuo
Publication of MA34738B1 publication Critical patent/MA34738B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)

Abstract

La présente invention concerne de nouveaux anticorps humanisés, chimères et murins ayant une spécificité de liaison au ligand 20 de la chimiokine CC humaine (CCL20). La présente invention concerne en outre des chaînes lourdes et des chaînes légères desdits anticorps. L'invention concerne également des acides nucléiques isolés, des vecteurs recombinants et des cellules hôtes comprenant une séquence codant pour une chaîne lourde et/ou une chaîne légère desdits anticorps, et un procédé de préparation desdits anticorps. Les anticorps anti-CCL20 de l'invention peuvent être utilisés dans des applications thérapeutiques destinées à traiter, par exemple, des troubles inflammatoires et autoimmuns et le cancer.
MA36013A 2010-11-19 2013-06-14 Neutralisation d'anticorps anti-ccl20 MA34738B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41561410P 2010-11-19 2010-11-19
PCT/US2011/061525 WO2012068540A2 (fr) 2010-11-19 2011-11-18 Neutralisation d'anticorps anti-ccl20

Publications (1)

Publication Number Publication Date
MA34738B1 true MA34738B1 (fr) 2013-12-03

Family

ID=46084688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36013A MA34738B1 (fr) 2010-11-19 2013-06-14 Neutralisation d'anticorps anti-ccl20

Country Status (25)

Country Link
US (3) US8491901B2 (fr)
EP (1) EP2640744A4 (fr)
JP (3) JP5996549B2 (fr)
KR (1) KR101919170B1 (fr)
CN (1) CN103874707B (fr)
AR (1) AR084141A1 (fr)
AU (2) AU2011329647B2 (fr)
BR (1) BR112013012396A2 (fr)
CA (1) CA2818548A1 (fr)
CL (1) CL2013001403A1 (fr)
CO (1) CO6761352A2 (fr)
CR (1) CR20130228A (fr)
DO (1) DOP2013000111A (fr)
EA (1) EA029419B1 (fr)
IL (1) IL226383B (fr)
MA (1) MA34738B1 (fr)
MX (1) MX361929B (fr)
NZ (1) NZ611269A (fr)
PE (2) PE20180249A1 (fr)
PH (1) PH12013500990A1 (fr)
SG (2) SG10201509499RA (fr)
TW (1) TWI589587B (fr)
UA (1) UA114077C2 (fr)
WO (1) WO2012068540A2 (fr)
ZA (3) ZA201303571B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361929B (es) * 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
CN105017420B (zh) 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
WO2014062659A2 (fr) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de maladies oculaires
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
WO2015179236A1 (fr) 2014-05-21 2015-11-26 Pfizer Inc. Combinaison d'un anticorps anti-ccr4 et d'un agoniste a 4-1bb pour le traitement du cancer
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3233112A2 (fr) * 2014-12-17 2017-10-25 Cancer Research Technology Limited Molécules d'anticorps anti-cxcl12 et leurs utilisations
JP6786526B2 (ja) 2015-06-03 2020-11-18 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 改変されたｃｃｌ２０ロックド二量体ポリペプチド
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
KR20180027568A (ko) * 2015-07-14 2018-03-14 메디뮨 엘엘씨 암을 치료하기 위한 조성물 및 방법
WO2017064564A2 (fr) * 2015-10-16 2017-04-20 Glaxosmithkline Intellectual Property Limited Régimes thérapeutiques pour traiter l'arthrite psoriatique avec un anticorps anti-ccl20
US11305010B2 (en) * 2016-01-21 2022-04-19 The Scripps Research Institute Synthetic opioid vaccine
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
SG11201903800XA (en) * 2016-11-14 2019-05-30 Dinona ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
FR3072779A1 (fr) * 2017-10-19 2019-04-26 Sinnovial Procede d'estimation de l'efficacite d'un modulateur de la costimulation des lymphocytes t contre la polyarthrite rhumatoide apres reponse inadequate a une biotherapie
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
CN111587123A (zh) * 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
WO2020185952A1 (fr) * 2019-03-11 2020-09-17 xCella Biosciences, Inc. Anticorps se liant à cd27 et leurs utilisations
TWI884192B (zh) 2019-12-05 2025-05-21 美商西健公司 抗αＶβ６抗體及抗體-藥物結合物
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
CN117242334A (zh) * 2021-04-21 2023-12-15 高丽大学校产学协力团 用于检测自噬标志物的高灵敏度纳米等离子体生物传感器、其制造方法、以及使用其的自噬标志物检测方法
JP2024534053A (ja) * 2021-08-25 2024-09-18 アイバイオ， インク． 抗ｃｄ２５抗体
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN120518762B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
CN119139478A (zh) * 2024-10-11 2024-12-17 首都医科大学附属北京胸科医院 一种治疗anxa6+egfr突变的肺腺癌的组合物

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897348A (en) 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
JP3051160B2 (ja) 1988-12-08 2000-06-12 ノバルティス・アクチエンゲゼルシャフト 好中球活性化ペプチド‐２
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
DE69020573T3 (de) 1989-09-25 1999-12-16 Crc Technology Ltd., London Verfahren zur wachstumshemmung von stammzellen.
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0548214B1 (fr) 1990-09-14 1999-03-10 Chiron Corporation Expression de proteines inductibles par macrophages (mip) dans des cellules de levure
FR2669930A1 (fr) 1990-11-29 1992-06-05 Sanofi Sa Proteine presentant une activite de type cytokine, adn recombinant, vecteur d'expression et hotes permettant son obtention.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5306709A (en) 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5413778A (en) 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
US5346686A (en) 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
WO1994026087A2 (fr) 1993-05-14 1994-11-24 Connor Kim C O Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH0789866A (ja) 1993-09-21 1995-04-04 Nippon Kayaku Co Ltd 感染防御剤
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1995017092A1 (fr) 1993-12-22 1995-06-29 Human Genome Sciences, Inc. PROTEINES-3, -4 ET 1η INFLAMMATOIRES MACROPHAGES
ATE206162T1 (de) 1994-05-16 2001-10-15 Human Genome Sciences Inc Chemotaktisches protein
AU7394294A (en) 1994-05-16 1995-12-05 Human Genome Sciences, Inc. Macrophage migration inhibitory factor-3
EP0777494B1 (fr) 1994-08-23 2004-03-24 Human Genome Sciences, Inc. Polypeptides de type chemokine humaine
JPH10508742A (ja) 1994-08-23 1998-09-02 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒトケモカインポリペプチド
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US5981230A (en) 1994-08-23 1999-11-09 Human Genome Sciences, Inc. Polynucleotide encoding chemokine β-4
WO1996006169A1 (fr) 1994-08-23 1996-02-29 Human Genome Sciences, Inc. Chemokine beta 9 humaine
ES2216001T3 (es) 1994-08-23 2004-10-16 Human Genome Sciences, Inc. Polipeptidos de quimioquina humana.
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
WO1996009062A1 (fr) 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子−γ
US5602008A (en) 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
CN1190991A (zh) 1995-06-05 1998-08-19 人类基因组科学公司 人类趋化因子β－11和人类趋化因子α－1
AU2698795A (en) 1995-06-06 1996-12-24 Human Genome Sciences, Inc. Human chemokine beta-12
WO1996039521A1 (fr) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Chemokine beta-13 humaine
JP2001519757A (ja) 1995-10-24 2001-10-23 スミスクライン・ビーチャム・コーポレイション 幹細胞動員のための新規ケモカイン
ZA968896B (en) 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
AU5355996A (en) 1996-02-23 1997-09-10 Human Genome Sciences, Inc. Human chemokine polypeptides
WO1997033904A1 (fr) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
WO1997033899A1 (fr) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Molecule i induisant l'apoptose
WO1997035982A2 (fr) 1996-03-27 1997-10-02 Icos Corporation Materiels et procedes de fabrication de proteine-5 chimiotactique monocyte
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
WO1998001557A2 (fr) 1996-07-05 1998-01-15 Schering Corporation Reactifs apparentes a des chemokines mammaliennes
WO1998007880A1 (fr) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Endokine alpha humaine
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
GB9617923D0 (en) 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
WO1998011226A2 (fr) 1996-09-10 1998-03-19 Schering Corporation Chemokines de mammiferes et reactifs apparentes
WO1998014573A1 (fr) 1996-09-30 1998-04-09 The General Hospital Corporation Nouvelles chimiokines mcp-4 et mcp-5
WO1998017800A1 (fr) 1996-10-17 1998-04-30 Shionogi & Co., Ltd. Larc, nouvelle chimiokine cc humaine
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
IL125351A0 (en) 1996-11-15 1999-03-12 Indiana University Foundation Exodus chemokine materials and methods
US7101987B2 (en) * 1996-11-27 2006-09-05 Schering Corporation CCL27 polypeptides
EP0990031B1 (fr) 1997-01-14 2006-03-29 Human Genome Sciences, Inc. Recepteur 5 du facteur de necrose tumorale
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
NZ508381A (en) 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
WO1998049309A1 (fr) 1997-04-30 1998-11-05 F. Hoffmann-La Roche Ag Chemokine st38.2 du rat
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
US6214580B1 (en) 1997-05-30 2001-04-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
CA2295991A1 (fr) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Recepteur humain tr9 du facteur de necrose tumorale
AU3094999A (en) 1998-03-18 1999-10-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6645491B1 (en) 1999-02-03 2003-11-11 Schering Corporation Method for treating inflammatory conditions using an antibody to MIP-3α
WO2000046248A1 (fr) * 1999-02-03 2000-08-10 Schering Corporation Utilisation d'agonistes ou d'antagonistes de la chimiokine mip-3a a des fins therapeutiques
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20040197329A1 (en) 2000-10-13 2004-10-07 Yasunori Nakayama Remedies or preventives for rheumatoid arthritis
EP1370589B1 (fr) * 2000-12-05 2006-03-15 Alexion Pharmaceuticals, Inc. Anticorps concus de maniere rationnelle
ATE347695T1 (de) 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
ATE518884T1 (de) 2002-05-01 2011-08-15 Human Genome Sciences Inc Spezifisch an chemokin beta-4 bindende antikörper
JP2007521249A (ja) 2003-01-24 2007-08-02 エラン ファーマシューティカルズ，インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
WO2005017149A1 (fr) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
EP1694706B1 (fr) 2003-11-01 2012-04-04 Merck Patent GmbH Anticorps anti-cd52 modifie
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
CA2597098C (fr) 2005-02-08 2016-08-02 Steven R. Ledbetter Anticorps anti-tgf-beta
JP2009096716A (ja) * 2006-01-19 2009-05-07 Eisai R & D Management Co Ltd 抗ｃｃｌ２０抗体による自己免疫疾患の治療
WO2009077483A1 (fr) * 2007-12-14 2009-06-25 Novo Nordisk A/S Anticorps humains anti-nkg2d et leurs utilisations
WO2009062050A2 (fr) * 2007-11-08 2009-05-14 Neogenix Oncology, Inc. Anticorps monoclonaux recombinants et antigènes correspondants pour des cancers du côlon et du pancréas
WO2009156994A1 (fr) * 2008-06-24 2009-12-30 Hadasit Medical Research Services And Development Ltd. Anticorps spécifiques de ccl20 pour la thérapie du cancer
EP2352763B2 (fr) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Anticorps monocaténaires bispécifiques spécifiques d'antigènes cibles de masse moléculaire élevée
MX361929B (es) * 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
WO2013005649A1 (fr) * 2011-07-01 2013-01-10 協和発酵キリン株式会社 Anticorps anti-ccr6 humain
JP7089866B2 (ja) 2017-12-22 2022-06-23 セーレン株式会社 開口部を有するシート状物およびその製造方法

Also Published As

Publication number Publication date
CN103874707B (zh) 2017-04-19
US8491901B2 (en) 2013-07-23
SG191716A1 (en) 2013-08-30
TWI589587B (zh) 2017-07-01
US20160046707A1 (en) 2016-02-18
ZA201701051B (en) 2018-05-30
KR101919170B1 (ko) 2018-11-15
JP5996549B2 (ja) 2016-09-21
WO2012068540A2 (fr) 2012-05-24
ZA201406017B (en) 2017-06-28
PE20180249A1 (es) 2018-02-02
CL2013001403A1 (es) 2014-08-08
US20120148592A1 (en) 2012-06-14
EA201390738A1 (ru) 2013-12-30
US9133273B2 (en) 2015-09-15
CO6761352A2 (es) 2013-09-30
US9809647B2 (en) 2017-11-07
US20140045215A1 (en) 2014-02-13
AU2011329647B2 (en) 2015-10-22
UA114077C2 (xx) 2017-04-25
ZA201303571B (en) 2014-12-23
EP2640744A4 (fr) 2014-05-28
IL226383A0 (en) 2013-07-31
AR084141A1 (es) 2013-04-24
EP2640744A2 (fr) 2013-09-25
JP2018042578A (ja) 2018-03-22
MX361929B (es) 2018-12-19
PH12013500990A1 (en) 2022-11-23
JP2016093195A (ja) 2016-05-26
CR20130228A (es) 2013-09-18
SG10201509499RA (en) 2015-12-30
WO2012068540A3 (fr) 2012-09-27
BR112013012396A2 (pt) 2020-11-10
CA2818548A1 (fr) 2012-05-24
MX2013005532A (es) 2013-09-26
JP6289520B2 (ja) 2018-03-07
PE20140633A1 (es) 2014-05-30
DOP2013000111A (es) 2014-06-15
EA029419B1 (ru) 2018-03-30
CN103874707A (zh) 2014-06-18
AU2016200359A1 (en) 2016-02-11
JP2014502154A (ja) 2014-01-30
AU2016200359B2 (en) 2018-05-24
AU2011329647A1 (en) 2013-05-02
KR20130135872A (ko) 2013-12-11
IL226383B (en) 2018-07-31
TW201305204A (zh) 2013-02-01
NZ611269A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
PH12013500990A1 (en) Neutralizing anti-ccl20 antibodies
MA32621B1 (fr) Traitement de maladie auto-immune et inflammatoire
Fischer et al. Combined inhibition of tumor necrosis factor α and interleukin‐17 as a therapeutic opportunity in rheumatoid arthritis: Development and characterization of a novel bispecific antibody
MA37949B1 (fr) Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite
MA34383B1 (fr) Analogues de glucagon
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA43461A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA43330B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA33717B1 (fr) Immunoconjugués ciblés
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43322A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
WO2003104399A3 (fr) Gene lie au cancer servant de cible en chimiotherapie
MA46648A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
EP2532365A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
EP2532366A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
EP1566387A3 (fr) Gènes impliqués dans la régulation de l'angiogenese, préparations pharmaceutiques les contenant et leurs applications
TW200635946A (en) Binding proteins specific for human matriptase
FR3132634B1 (fr) Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant
MA33668B1 (fr) Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer
Nekrasova et al. Receptor-binding domain of ephrin-A1: Production in bacterial expression system and activity
WO2003104419A3 (fr) Gene lie au cancer utilise en tant que cible pour la chimiotherapie